Artificial intelligence (AI) s a branch of computer science concerned with the development of intelligent systems capable of reasoning, learning, and acting autonomously. This is no longer a peripheral technology as it has become deeply embedded across disciplines and the research community is no exception. At its core, AI leverages machine learning (ML) to process data, identify patterns, and generate outputs that increasingly inform critical decisions. Its utility is well-documented: from accelerating literature synthesis to enhancing diagnostic precision in clinical research.
The convergence of AI and biotechnology termed AIxBio, represents one of the most transformative scientific advancement. This rapidly evolving field combines Machine Learning (ML), Deep Learning (DL), Generative AI and high- throughput biological systems to accelerate scientific discovery and improve research. Its potentials to accelerate innovations in drug discovery and improve bio manufacturing cannot be disputed, but at the same time, the rapid advancement of frontier AI systems raises unprecedented concerns regarding dual-use risks, AI-enabled biological threats, and governance challenges.
The risk profile of AI systems is fundamentally distinct from that of conventional software. Unlike traditional systems, AI is probabilistic, data-dependent, and highly scalable. These characteristics allow even minor errors to propagate into large-scale, consequential harm. In AIxBIO, this concern is particularly acute as the informational nature of AI-driven bio-threats, in contrast to the material nature of traditional biological threats, complicates monitoring and necessitates a nuanced approach to risk mitigation.
Presently, traditional risk assessment frameworks are insufficient for AIxBio systems. There is the urgent need for active governance of AIxBIO. The following actions are critical in respect to Governing AIxBIO.
governance will depend on international cooperation, ethical oversight, adaptive regulation, secure technological design, and responsible scientific collaboration.
As researchers, and members of FABA, we have both the responsibility and the capacity to lead on this The conversation around AIxBio governance must move from the margins to the centre of our scholarly discourse.
I would love to hear from you: Is your institution actively addressing AI governance within its biotechnology research frameworks?
